PRODUCT – Page 8

Regeneron Acquires UK-Based Eye Drug Developer Oxular

8 months ago talkbio0Tagged Acquisition, eye drug development, Oxular, Regeneron, Retina

Regeneron, Oxular, eye drug development, retinal therapeutics, acquisition

FDA Approves ALYFTREK, a Next-Generation CFTR Modulator for Cystic Fibrosis Treatment

9 months ago talkbio0Tagged ALYFTREK, Approved, CFTR, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Modulator Device, once-daily, United States Food and Drug Administration

ALYFTREK, cystic fibrosis, CFTR modulator, FDA approval, once-daily treatment, Vertex Pharmaceuticals

Mesoblast Secures FDA Approval for Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease

9 months ago talkbio0Tagged Approved, Cell Therapy, Mesenchymal Stromal Cell Therapy, Mesoblast, Pediatric brand name, Ryoncil, SR-aGVHD, Steroid-Refractory Acute Graft-Versus-Host Disease, United States Food and Drug Administration

Mesoblast, Ryoncil, FDA Approval, Mesenchymal Stromal Cell Therapy, Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD), Pediatric Patients, Cell Therapy

Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion

9 months ago talkbio0Tagged Bayer, Biosimilars, competition, expansion, Eylea HD, Macular retinal edema, Phase 3 Clinical Trials, Regeneron, Retinal Vein Occlusion

Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition

iTeos Therapeutics Deprioritizes Inupadenant Despite Encouraging Phase 2 Data in NSCLC

9 months ago talkbio0Tagged Adenosine A2A Receptor Antagonist, deprioritization, Inupadenant, iTeos, Non-Small Cell Lung Carcinoma, Phase 2 trial

iTeos Therapeutics, Inupadenant, Adenosine A2A Receptor Antagonist, NSCLC, Phase 2 Trial, Deprioritization

Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks

9 months ago talkbio0Tagged Acelyrin, Arthritis, Psoriatic, biotech, Clinical Trials, Failure (biologic function), Hidradenitis, Immunology, IPO, Izokibep, suppurativa

Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO

uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130

9 months ago talkbio0Tagged Accelerated, AMT-130, Approved, cUHDRS, gene therapy, Huntington 's disease, NEFL gene, NfL, Regenerative Medicine, RMAT, UniQure, United States Food and Drug Administration

uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)

Zelicapavir Shows Promising Antiviral Effect in Pediatric RSV Study

9 months ago talkbio0Tagged Antiviral Agents, Pediatric brand name, Phase 2 Clinical Trials, Respiratory syncytial virus, Zelicapavir

Zelicapavir, RSV, Antiviral, Pediatric, Phase 2 Study, Respiratory Syncytial Virus

Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases

9 months ago talkbio0Tagged Autoimmune Diseases, Chronic Idiopathic Demyelinating Polyneuropathy, CIDP, Fc Ab fragments, Nuvig, NVG-2089, Phase 2 Clinical Trials, Recombinants, synthetic manufacturing

Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.

Philips and AWS Strengthen Strategic AI Partnership, Expanding Cloud-Enabled Diagnostics to Europe

10 months ago talkbio0Tagged Alagille Syndrome, Diagnostics, European (ethnic group), expansion, Generative AI, healthcare innovation, Integrated Diagnostics Portfolio, Philips, Strategic AI Collaboration

Philips, AWS, Strategic AI Collaboration, Cloud-Enabled Diagnostics, European Expansion, Healthcare Innovation, Integrated Diagnostics Portfolio, Generative AI Applications